Valuation: SANA AB

Market Cap 1.34B 135M 119M 112M 102M 191M 12.95B 192M 519M 6.62B 507M 496M 21.27B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.34B 135M 119M 112M 102M 191M 12.95B 192M 519M 6.62B 507M 496M 21.27B EV / Sales 2026 *
13x
EV / Sales 2027 * 6.41x
Free-Float
90.64%
Yield 2026 *
-
Yield 2027 * -
1 day-1.12%
1 week-2.90%
Current month-15.12%
1 month-17.92%
3 months-24.55%
6 months-39.61%
Current year-54.20%
1 week 9.46
Extreme 9.455
10.34
1 month 9.46
Extreme 9.455
12.5
Current year 9.46
Extreme 9.455
28.3
1 year 9.46
Extreme 9.455
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 2025-02-28
Chief Executive Officer 66 2022-04-29
Chief Tech/Sci/R&D Officer 68 2013-12-31
Director TitleAgeSince
Chairman 71 2022-04-29
Director/Board Member 68 2014-12-31
Director/Board Member 46 2018-01-18
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 Buy

Chairman

50,000 0.0362%
9/1/26 Buy

Founder

9,000 0.0065%
8/28/26 Buy

Chief Financial Officer

5,000 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
-1.12%-2.90%-18.54%+59.70% 136M
-3.30%+1.50%+51.24%+99.26% 71.94B
+1.25%-3.01%+40.12%+77.12% 59.35B
+2.12%+5.26%+32.50%+21.28% 27.16B
-3.06%-1.81%-13.10%+357.06% 26.54B
-0.75%+2.56%+0.45%-4.46% 24.93B
+0.40%+0.75%+22.91%-9.68% 20.61B
-1.70%-2.12%+146.86%+314.52% 15.03B
+0.21%+1.17%-8.07%+499.10% 14.2B
+0.36%-0.34%+50.32%+166.42% 14.36B
Average -0.56%-0.14%+30.47%+158.03% 27.43B
Weighted average by Cap. -0.78%-0.02%+36.09%+130.08%

Financials

2026 *2027 *
Net sales 103M 10.4M 9.12M 8.62M 7.85M 14.7M 996M 14.8M 39.93M 509M 39.03M 38.19M 1.64B 209M 21.09M 18.51M 17.48M 15.93M 29.82M 2.02B 30.04M 81.03M 1.03B 79.2M 77.49M 3.32B
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
44
Date Price Change Volume
26-09-25 SEK 9.710 -1.12% 379,612
26-09-24 SEK 9.820 -0.81% 387,361
26-09-23 SEK 9.900 -1.69% 259,760
26-09-22 SEK 10.07 +5.45% 443,585
26-09-21 SEK 9.550 -4.50% 683,024

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock